Astra Zeneca
AstraZeneca PLC, a leading global biopharmaceutical company, is headquartered in Cambridge, GB. Founded in 1999 through the merger of Astra AB and Zeneca Group PLC, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in the research, development, and manufacturing of innovative medicines, AstraZeneca focuses on areas such as oncology, cardiovascular, renal, and respiratory diseases. With a commitment to advancing healthcare, AstraZeneca is renowned for its unique portfolio of products, including groundbreaking therapies like Tagrisso and Imfinzi. The company has achieved significant milestones, including rapid vaccine development during the COVID-19 pandemic, solidifying its position as a market leader in the pharmaceutical industry. AstraZeneca continues to drive innovation, aiming to improve patient outcomes worldwide.
DitchCarbon Score
How does Astra Zeneca's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astra Zeneca's score of 43 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Astra Zeneca's reported carbon emissions
In 2023, AstraZeneca reported total greenhouse gas emissions of approximately 6,736,877,000 kg CO2e, with emissions distributed across various scopes: 180,898,000 kg CO2e from Scope 1, 19,940,000 kg CO2e from Scope 2, and 6,736,877,000 kg CO2e from Scope 3. The company has set ambitious climate commitments, aiming for net-zero emissions across its value chain by FY2045. AstraZeneca's near-term targets include a significant reduction of 98% in absolute Scope 1 and 2 emissions by FY2026, using 2015 as the baseline year. Additionally, the company aims to cut absolute Scope 3 emissions by 50% by FY2030, with specific targets for various categories: an 80% reduction in emissions from fuel and energy-related activities, upstream leased assets, and downstream leased assets; a 95% reduction from the use of sold products; and a 46% reduction from upstream transportation and distribution, waste generated in operations, business travel, employee commuting, and end-of-life treatment of sold products, all from a 2019 baseline. Furthermore, AstraZeneca is committed to ensuring that 95% of its suppliers by spend on purchased goods and services and capital goods, and 50% of suppliers by spend on upstream transportation and distribution and business travel, will have science-based targets by FY2025. Long-term, the company aims for a 90% reduction in absolute Scope 3 emissions by FY2045 from the 2019 baseline. These initiatives reflect AstraZeneca's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astra Zeneca is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
